

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims in the application:

Claim 1 (currently amended): A composition comprising a construct, wherein the construct comprises:

- (a) a complement receptor 2 (CR2) ~~CR2~~ or a fragment thereof, wherein the fragment contains at least the first two N-terminal short consensus repeat (SCR) ~~SCR~~ domains of the CR2 protein; and
- (b) a modulator of complement activity, wherein the modulator comprises CD59.

Claim 2 (original): The composition of claim 1, wherein the construct is a fusion protein.

Claims 3-8 (canceled).

Claim 9 (currently amended): The composition of claim ~~[[8]]~~ 1, wherein the composition comprises SEQ ID NO. 12.

Claim 10 (currently amended): The composition of claim ~~[[8]]~~ 1, wherein the composition comprises SEQ ID NO. 8.

Claims 11-16 (canceled)

Claim 17 (currently amended): The composition of claim ~~[[8]]~~ 1, wherein the complement ~~inhibitor~~ modulator is murine CD59 or human CD59.

Claims 18-28 (canceled).

Claim 29 (withdrawn): The composition of claim 1, wherein the construct is an immunoconjugate.

Claim 30 (withdrawn): A method of treating a condition affected by complement in a subject comprising administering to the subject the composition of any of claims 1, 2, 4, 19 or 52.

Claim 31 (withdrawn): The method of claim 30, wherein the condition is a cancer.

Claim 32 (canceled).

Claim 33 (withdrawn): The method of claim 30, wherein the condition is selected from the group consisting of a viral infection, a bacterial infection, a parasitic infection, and a fungal infection.

Claims 34-40 (canceled).

Claim 41 (withdrawn): The method of claim 30, wherein the condition is an inflammatory condition.

Claims 42-45 (canceled).

Claim 46 (withdrawn): A method of reducing complement-mediated damage comprising administering to a subject the composition of any of claims 1, 2, 4 or 52.

Claim 47 (withdrawn): A method of enhancing complement-mediated damage comprising administering to a subject the composition of any of claims 1, 2, 19 or 52.

Claim 48 (previously presented): The composition of claim 2, wherein the CR2 or a fragment thereof is fused to the N-terminus of the modulator of complement activity.

Claim 49 (previously presented): The composition of claim 2, wherein the CR2 or a fragment thereof is fused to the C-terminus of the modulator of complement activity.

Claim 50 (previously presented): The composition of claim 1, wherein the CR2 or a fragment thereof comprises a full-length CR2 protein.

Claim 51 (previously presented): The composition of claim 1, wherein the CR2 or a fragment thereof comprises the four N-terminal SCR domains of the CR2 protein.

Claim 52-53 (canceled).

Claim 54 (currently amended): The composition of claim [[4]] 1, wherein the complement ~~inhibitor~~ modulator comprises the extracellular region of CD59.

Claim 55 (withdrawn): A method of targeting a modulator of complement activity to a site of complement activation in a subject by administering to the subject a composition of any of claims 1, 2, 4, 8, 17, 19 or 52.

Claim 56 (withdrawn): A method of treating an inflammatory condition in a subject by administering to the subject a composition of any of claims 1, 2, 4, 8, 17 or 52.

Claim 57 (withdrawn): The method of claim 56, wherein the inflammatory condition is stroke.

Claim 58 (withdrawn): The method of claim 56, wherein the inflammatory condition is ischemia reperfusion injury.

Claim 59 (withdrawn): A nucleotide sequence encoding a fusion protein of claim 2.

Claims 60-82 (canceled).